Evolus (EOLS) Notes Payables (2017 - 2021)

Evolus (EOLS) posted Notes Payables of $20.0 million for Q3 2021, up 1.54% on a QoQ basis from $19.6 million in Q2 2021.

Evolus (EOLS) Notes Payables (2017 - 2021) Analysis & Trends

Evolus' Notes Payables history runs 3 years deep, the most recent figure standing at $20.0 million for Q3 2021.

  • Quarterly Notes Payables changed N/A year-over-year to $20.0 million in Q3 2021, while the trailing twelve-month figure through Sep 2021 was $20.0 million (changed N/A YoY) and the FY2020 annual result came in at $19.1 million, changed N/A from the prior year.
  • Notes Payables was $20.0 million for Q3 2021 at Evolus, up from $19.6 million in the prior quarter.
  • Across five years, Notes Payables topped out at $138.7 million in Q4 2017 and bottomed at $19.1 million in Q4 2020.
  • A 3-year average of $43.3 million and a median of $19.6 million in 2021 frame the typical range for Notes Payables.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Haleon 87.22 Bn 85.35 Bn -
2 Teva Pharmaceutical Industries 39.60 Bn 35.87 Bn 1.97 Bn
3 Zoetis 31.46 Bn 29.52 Bn 1.62 Bn
4 Takeda Pharmaceutical 26.49 Bn 22.44 Bn 4.39 Bn
5 United Therapeutics 23.03 Bn 20.88 Bn 648.10 Mn
6 Universe Pharmaceuticals 23.03 Bn -10.56 Bn -
7 Viatris 20.90 Bn 19.09 Bn 1.16 Bn
8 Neurocrine Biosciences 17.50 Bn 16.19 Bn 800.70 Mn
9 Elanco Animal Health 12.33 Bn 11.91 Bn 785.00 Mn
10 Evolus 390.47 Mn 340.68 Mn 48.90 Mn

Historic Data

Download Data
DateValue
Sep 30, 2021 19.95 Mn
Jun 30, 2021 19.65 Mn
Mar 31, 2021 19.35 Mn
Dec 31, 2020 19.07 Mn
Dec 31, 2017 138.69 Mn